From Financialpost · · 50s
Helus Pharma Advances Mental Health Treatments
Helus Pharma reports progress on two mental health drugs for depression and anxiety.
In brief
Helus Pharma reports progress on two mental health drugs for depression and anxiety. Helus Pharma's HLP003 and HLP004 programs show progress in clinical trials for depression and anxiety treatments. Originally reported by Financialpost.
Helus Pharma Investor Presentation
Helus Pharma held an investor presentation on October 21, 2026.
HLP003 Phase 3 Study
HLP003's APPROACH Phase 3 topline data readout is on track for Q4 2026.
HLP004 Phase 2 Study
HLP004's Phase 2 monotherapy study for generalized anxiety disorder starts in Q1 2027.
FDA Breakthrough Designation
HLP003 has FDA Breakthrough Therapy Designation for expedited review.
CEO Statement
CEO Michael Halstead says Helus Pharma is focused on regulatory approval and commercialization.
Next Steps
Helus Pharma expects to file a New Drug Application with the FDA in 2028.
At a glance
Helus Pharma's HLP003 and HLP004 programs show progress in clinical trials for depression and anxiety treatments.
